What is Mesh Bio?
Mesh Bio operates at the intersection of healthcare and data science, specializing in the development of clinical decision support analytics. Its flagship offering, the DARA Health Intelligence Platform, is engineered to address the complexities of managing chronic conditions such as cardiovascular disease. By automating care delivery and enhancing patient engagement, the platform provides clinicians with actionable insights that improve health outcomes. The company's market position is defined by its focus on interoperability and the integration of health intelligence into existing clinical workflows, effectively bridging the gap between raw patient data and personalized treatment strategies.
How much funding has Mesh Bio raised?
Mesh Bio has raised a total of $5.3M across 2 funding rounds:
Angel/Seed
$1.8M
Series A
$3.5M
Angel/Seed (2021): $1.8M with participation from CITRINE CAPITAL, Elev8.vc, SEED Capital, and Tael Partners
Series A (2024): $3.5M led by East Ventures
Key Investors in Mesh Bio
East Ventures
A prominent venture capital firm in Southeast Asia, focusing on supporting visionary founders from Seed to Growth stages with an emphasis on sustainable development and ESG-driven initiatives.
CITRINE CAPITAL
An investment firm providing strategic capital to high-growth companies, often focusing on scalable technology solutions and market-disrupting business models.
SEED Capital
A Denmark-based venture capital firm specializing in early-stage investments, providing both financial backing and operational expertise to innovative technology startups.
What's next for Mesh Bio?
With the recent infusion of capital, Mesh Bio is expected to prioritize the expansion of its DARA platform, focusing on broader market penetration and the enhancement of its predictive analytics capabilities. The strategic roadmap likely includes scaling operations to meet the needs of larger healthcare providers and health systems, thereby solidifying its footprint in the digital health sector. As the company matures, the focus will shift toward demonstrating long-term clinical efficacy and operational efficiency, which are essential for sustained growth in the competitive health-tech landscape. Investors will be monitoring the firm's ability to integrate its solutions into diverse clinical environments while maintaining high standards of data security and patient care quality.
See full Mesh Bio company page
